News
Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.
The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's ...
The agreement grants Weston N.V. access to up to €100 million over a 36-month period following a public listing company's stock. Through a share subscription facility, Weston N.V. will be permitted to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results